Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity and Treatment Regimens of VTP-300 Combined With Low-dose Nivolumab in Chronic Hepatitis B Infection

Next Previous
Trial Profile

A Phase 2b, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity and Treatment Regimens of VTP-300 Combined With Low-dose Nivolumab in Chronic Hepatitis B Infection

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; VTP 300 (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Barinthus Biotherapeutics

Most Recent Events

  • 07 May 2025 According to Barinthus Biotherapeutics media release, 6-month primary analysis of this study will be showcased in poster presentations at the European Association for the Study of the Liver (EASL) Congress 2025, taking place May 7-10, 2025, in Amsterdam, the Netherlands.
  • 10 Jan 2025 According to Barinthus Biotherapeutics media release, results from this study are expected in the second quarter of 2025.
  • 10 Jan 2025 According to Barinthus Biotherapeutics media release, the Company will not invest in VTP-300 in chronic hepatitis B beyond the completion of this study, and will further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identified, who are able to take advantage of this therapy to achieve sustained HBsAg loss and functional cure in patients with low levels of HBsAg.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top